Nuvolab seminar for Accelmed 2014: "Approaching investors"

91
APPROACHING INVESTORS Accelmed Accelera6on Programme July 29 2014

description

DETAILS of THE SEMINAR: Title: ACCELMED WEBINAR "Approaching Investors" Time: 29/7/2014 - 14.30 to 15.30 Trainer: Francesco Inguscio, Nuvolab srl Objective: The webinar on "Approaching investors"will help start-ups understand the process to fund a new company, identify different funding possibilities and know about process and tacite rules to approach and negociate a deal with an investor. Contents: - Overview - An inconvenient truth - Finding funding: different sources - How to approach investors - Conclusions Francesco Inguscio - Bio Francesco Inguscio is CEO and founder of Nuvolab, one of the main venture accelerator for startups in Italy. In 2010 he worked for M31, one of the most important business incubator in Italy as Business Development Director of its Silicon Valley branch, M31 USA. Formerly, he has been working both for the US Market Access of San Jose, a first rate international start-ups incubator in Silicon Valley, as business developer, and for the Angels’ Forum of Palo Alto, a leading business angel network in California, as financial analyst. In March 2010 he was awarded with his team of VRMedia, at Stanford University, with the Mind The Bridge prize, as the most innovative high tech startup in Italy. Previously, among others, he succeeded in working as research fellow in School of Advanced Studies Sant’Anna of Pisa (2009); as analyst IBM Global Business Services (2008) on market planning and IP management projects; as business strategy analyst in Accenture Business Consulting (2006), where he was involved in several projects concerning marketing and strategy analysis for the banking & insurance industry, and in the development of new financial products; he also worked in Prometeia (2005), a financial firm where he supported the development of innovative financial products and the creation of risk management tools for the banking industry. Francesco earned a BA in Management & Finance magna cum laude in 2003 and a MA in Finance magna cum laude in 2005, both from the University of Padova. In 2008, he got a Master in Innovation Management cum laude at the School Sant’Anna of Pisa. Currently; in 2010 he earned a Certificate in Technology Entrepreneurship at the Santa Clara University (CA), supported by the Fulbright BEST Program Grant.

Transcript of Nuvolab seminar for Accelmed 2014: "Approaching investors"

Page 1: Nuvolab seminar for Accelmed 2014: "Approaching investors"

APPROACHING  INVESTORS    

Accelmed  Accelera6on  Programme  July  29  2014  

Page 2: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions    

Page 3: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Nuvolab   is   a   business   accelerator   and   a   catalyst   of  change   dedicated   to   all   the   reali=es   in   the   (Italian)  entrepreneurial  ecosystem.  

What  is  Nuvolab?  

Page 4: Nuvolab seminar for Accelmed 2014: "Approaching investors"

What  is  a  startup?  

Page 5: Nuvolab seminar for Accelmed 2014: "Approaching investors"

What  is  a  startup?  

An  innova=ve    company  

Page 6: Nuvolab seminar for Accelmed 2014: "Approaching investors"

A   startup   is   temporary   organiza6on   in   search   of   a   repeatable,  scalable   business   model   (Steve   Blank,   The   Startup   Owner’s  Manual)  1.   Temporary  organiza6on  2.   In  search  3.   Of  a  business  model  4.   Repeatable  5.   Scalable  

A  good  defini6on  

Page 7: Nuvolab seminar for Accelmed 2014: "Approaching investors"

A   startup   has   a   well   defined   lifecycle   that   ends   with   the   valida=on   of   its  (repeatable  and  scalable)  business  model.    Done  that,  it  becomes  a  real  “company”.  It’s  a  journey.  

Temporary  organiza6on…  

Page 8: Nuvolab seminar for Accelmed 2014: "Approaching investors"

A  startup  is  a  “?”  and  not  a  “!”  (more  appropriate  for  successful  company)  beside  the  word  “business  model”.    

Credits:  Steve  Blank,  The  Startup  Owner’s  Manual  

Credits:  Eric  Ries,  The  Lean  Startup  

?  

..in  search...  

Page 9: Nuvolab seminar for Accelmed 2014: "Approaching investors"

A   business   model   describes   the   ra=onale   of   “how   an   organiza+on   creates,  delivers,  and  captures  value”  (A.  Osterwalder,  2010).  In  other  words  is  about  how  a  firm  will  make  money  and  sustain  its  profit  stream  over  =me.  

..of  a  business  model...  

Page 10: Nuvolab seminar for Accelmed 2014: "Approaching investors"

A  repeatable  business  model,   is  a  business  model,  which  will  generate  cash-­‐flow  more  than   once.   This   sounds   very   obvious,  because   as   it   seems   every   business   is  repeatable.  But  this  is  not  true.    When   you   sell   your   house:   this   is   not   a  repeatable  business  model.    But   of   course   it   is   a   repeatable   business  model  to  sell  houses  of  other  people.    Repeatability   of   your   business   model   is  strongly   related   to   a   specific   ques=on:   if  your   business   will   growth   or   not   in   the  future.    

..repeatable...  

Page 11: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Scalability   is   the   ability   of   a   system,  network,   or   process   to   handle   a  growing   amount   of   work   in   a   capable  manner  or   its   ability   to  be  enlarged   to  accommodate  that  growth.  Meaning   for   a   business:   when   your  revenues   grow,   your   profits   grow  (more  than)  propor=onally  (economy  of  scale).  Scalability   of   your   business   model   is  strongly   related   to   a   specific   ques=on:  how   your   business   will   growth   in   the  future.  

..and  scalable!  

Page 12: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Not  every  (new)  company  is  a  (scalable)  startup.  •  A  startup  is  not  a  younger/smaller  version  of  an  “old”  

tradi=onal  company.  •  Startup  (=“?”):  a  temporary  organiza=on  in  search  of  a  

repeatable,  scalable  business  model  .  •  Company   (=“!”):   a   permanent   organiza=on   designed  

to  execute  a  repeatable  and  scalable  business  model    •  So  startups  have  (some)  different  needs  compared  to  

tradi=onal   companies   à   i.e.   financial   needs   and  funding  sources:  

–  Since  they  need  =me  (and  money)   in  order  to  find  an  answer  about   their   business   model   (“?”)  à   specific   funding   needs  (especially  when  their  business  is  capital  intensive)  

–  Since   they   are   high-­‐poten=al   (scalable)   companies   (“!”)   à  specific  (some6me  exclusive)  sources  of  finding  /  investors  

So  what?  

Page 13: Nuvolab seminar for Accelmed 2014: "Approaching investors"

The  startup  journey:  a  lifecycle  perspec6ve  (metaphor)  

Page 14: Nuvolab seminar for Accelmed 2014: "Approaching investors"

The  startup  journey:  a  lifecycle  perspec6ve  (metaphor)    

Page 15: Nuvolab seminar for Accelmed 2014: "Approaching investors"

STAGE 1 STAGE 2 STAGE 3

CONSERVATION  SUSTAIN  SCALE  EFFICIENCY  VALIDATION  DISCOVERY  IDEA  

STAGE 4 STAGE 5 STAGE 6 STAGE 7

REVE

NUES  

TIME  

Start   Launch  

Build  

Chasm  

Scale  

Maturity  

Source:  Four  Step  To  Epiphany  (S.  Blank),  Startup  Compass  (Stanford)  e  Startup  Lifecycle  (F.  Des=n)  

The  startup  journey:  a  lifecycle  perspec6ve  (product  PoV)  

Page 16: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions    

Page 17: Nuvolab seminar for Accelmed 2014: "Approaching investors"

STAGE 1 STAGE 2 STAGE 3

CONSERVATION  SUSTAIN  SCALE  EFFICIENCY  VALIDATION  DISCOVERY  IDEA  

STAGE 4 STAGE 5 STAGE 6 STAGE 7

REVE

NUES  

TIME  

Start   Launch  

Build  

Chasm  

Scale  

Maturity  

Source:  Four  Step  To  Epiphany  (S.  Blank),  Startup  Compass  (Stanford)  e  Startup  Lifecycle  (F.  Des=n)  

Startup  lifecycle:  take  the  product  PoV..  

Page 18: Nuvolab seminar for Accelmed 2014: "Approaching investors"

FINANCIAL  NEEDS  

7  STAGES  

CASH  FLOW  

EXPANSION MATURITY

Financial  needs  

Revenues  

Cumula6ve    cash  flow  

..and  combine  it  with  the  financial  PoV..  

Page 19: Nuvolab seminar for Accelmed 2014: "Approaching investors"

FINANCIAL  NEEDS  

7  STAGES  

CASH  FLOW  

EXPANSION MATURITY

Financial  needs  

Revenues  

Cumula6ve    cash  flow  

..where  the  financial  need  is  evident!  

Page 20: Nuvolab seminar for Accelmed 2014: "Approaching investors"

FASE 1 FASE 2 FASE 3

CONSERVATION  SUSTAIN  SCALE  EFFICIENCY  VALIDATION  DISCOVERY  IDEA  

FASE 4 FASE 5 FASE 6 FASE 7

Note:  overlapping  product  and  financial  perspec=ve  has  only  didac=c  purpose  

FINANCIAL  NEEDS  

7  STAGES  

CASH  FLOW  

EXPANSION MATURITY

Financial  needs  

Revenues  

Cumula6ve    cash  flow  

Start  

Launch  

Build  

Chasm  

Scale  

Maturity  

It  will  persist  6ll  your  business  model  is  validated  or..  

Page 21: Nuvolab seminar for Accelmed 2014: "Approaching investors"

FINANCIAL  NEEDS  

7  STAGES  

CASH  FLOW  

EXPANSION MATURITY

Financial  needs  

Revenues  

Cumula6ve    cash  flow  

“The  valley  of  death”    

..6ll  you  will  exit  from  the  market  prematurely  

Page 22: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Source:  The  Illusions  of  Entrepreneurship:  The  Costly  Myths  that  Entrepreneurs,  Investors,  and  Policy  Makers  Live  By  

HBS  (2011):  •  Failure  =  liquida=ng  all  

assets,  with  investors  losing  most  or  all  the  money  they  put  into  the  company  à  the  failure  rate  for  start-­‐ups  is  30-­‐40%.  

•  Failure  =  failing  to  see  the  projected  return  on  investment  à  failure  rate  is  70-­‐80%.    

•  Failure  =  declaring  a  projec6on  and  then  falling  short  of  mee=ng  it  à  failure  rate  is  a  whopping  90-­‐95%.    

Classic  company  

Tech  Startup  

The  Valley  of  Death  

Page 23: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Failure  rate  by  industry  

Page 24: Nuvolab seminar for Accelmed 2014: "Approaching investors"

6 Copyright © 2011 Nuvolab - All Rights Reserved

Fonte: http://www.chubbybrain.com/blog/top-reasons-startups-fail-analyzing-startup-failure-post-mortem/

Le 20 principali cause di “morte prematura” per una startup (secondo ChubbyBrain, database VC e BA)

Source:  h_p://www.chubbybrain.com/blog/top-­‐reasons-­‐  startups-­‐fail-­‐analyzing-­‐startup-­‐failure-­‐post-­‐mortem/  

The  top  20  Reasons  Startups  Fail  

Page 25: Nuvolab seminar for Accelmed 2014: "Approaching investors"

1.    Being  inflexible  and  not  ac=vely  seeking  or  using  customer  feedback  à  45%  

2.    Building  a  solu=on  looking  for  a  problem,  i.e.,  not  targe=ng  a  “market  need”  à  30%  

3.    Not  the  right  team  à  30%  4.    Poor  Marke=ng  à  28%  5.    Ran  out  of  cash  à  25%  6.    I  got  this  product.  Now  I  just  need  a  business  model  à  25%  

7.    Release  product  at  the  wrong  =me  à  20%  

8.    Lack  Passion  and  Exper=se  à  19%  9.    Do  not  cut  your  losses  a  la  Pivot  at  the  right  =me  à  19%  

10.    A  “User  Un-­‐Friendly”  Product  à16%  

11.    Pricing  Issues  à  16%  12.    Do  not  use  your  connec=ons  à  16%  13.    Disharmony  with  Investors/Co-­‐founders  à  12%    14.    Lose  Focus  –  Distracted  by  Shiny  Objects  à  12%    15.    Burn  Out  à  12%  16.    Get  outcompeted  à  10%  17.    Be  unable  to  A_ract  Investors  à  6%  18.    Loca=on,  Loca=on,  Loca=on  à  6%  19.    Not  working  on  it  full  =me  à  6%  20.    Start  the  company  at  the  wrong  =me  à  6%  

The  top  20  Reasons  Startups  Fail  

Page 26: Nuvolab seminar for Accelmed 2014: "Approaching investors"

So..  Startup  life  is  a  very  hard  thing!  

Page 27: Nuvolab seminar for Accelmed 2014: "Approaching investors"

SMART   MONEY  

Competences   Funding  What  is  missing?  

Page 28: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Verve  Capital   Partners   (2011):  what   is   the  VC  spent  per  capita  in  European  countries  (USA  $  67  pc)  à  5  groups  •  Group  1  ($70-­‐60):  Switzerland  ($69  pc),  the  

Netherlands  ($  62  pc)  •  Group   2   ($60-­‐50):   Sweden,   Finland   ($   59  

pc),   Denmark   ($   53   pc)…   over   European  average  ($  35  pc).  

•  Group   3   ($40-­‐30):   UK,   Ireland   ($39   pc),  Belgium  ($33  pc),  France  ($31  pc)  

•  Group   4   ($30-­‐20):   Norway   ($27   pc)   Spain  ($24  pc),  Germany  ($21  pc)  

•  Group  5   ($10-­‐0):  Austria   ($10  pc),  Portugal  ($  7  pc),  Greece  ($  3  pc)  and…last…  Italy  ($  1  pc)  

An  inconvenient  truth  

Page 29: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions    

Page 30: Nuvolab seminar for Accelmed 2014: "Approaching investors"

h_p://www.youtube.com/watch?v=U470xXKfDyE    

Let’s  start  with  a  brief  overview  (by  Kauffman  Founda6on)  

Page 31: Nuvolab seminar for Accelmed 2014: "Approaching investors"

“3  F”   BA   VC/CV   IPO  

FINANCIAL  NEEDS  

7  STAGES  

CASH  FLOW  

EXPANSION MATURITY

Financial  needs  

Revenues  

Cumula6ve    cash  flow  

Grant  Customers   Crowdfunding  Prizes  

Funding  your  startup:  (un)conven6onal  sources    

Page 32: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 33: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Where  to  spend  –  Team!  Engineers,  Product  

Management  –  Product  &  usability  –  Good  lawyers    

•  Where  NOT  to  spend:  –  Big  management  teams  –  Marke=ng  &  adver=sing  –  Big  outsourcing  projects  –  Bonuses  (with  some  

excep=ons…)  –  Travel  (again,  with  some  

excep=ons…)  –  Outside  sales  forces  

•  Common  spending  pitalls  –  Hiring  too  many  people  –  Hiring  the  wrong  people  –  Doing  too  many  things  –  Goldpla=ng  –  Not  geung  short-­‐term,  hard  

returns  

Especially  when  is  your  money:  cash  is  king  so..  

Page 34: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Financing  growth  from  previous  cashflow  and  personal  fund  (obviously  need  to  have  cashflows  J)  Most  good  bootstrapped  companies  emerge  from  a  service  or  consul=ng  companies  that  are  “produc=sing”  their  offering  Pros  

–  Bootstrapped  companies  almost  always  spend  cash  more  effec=vely  than  equity  financed  companies  

–  Already  being  close  to  exis=ng  customers,  give  excellent  ability  to  understand  problems  and  define  good  solu=ons  

Cons  –  Resources  for  product  and  market  dev  constrained  by  cashflows  –  May  miss  a  big  opportunity  if  other  players  raise  finance  and  invest  heavily  

 

Self  financing  /  bootstrapping  

Page 35: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Rela=vely  limited  funds  will  be  available  for  startup;  likely  to  want  collaterals  anyway  

•  Banks  only  lend  to  predictable  businesses  they  can  understand  (be_er  being  a  “!”  rather  than  a  “?”)  

•  If  your  capital  requirements  are  limited  and  your  business  is  following  a  well  trodden  path,  can  be  a  useful  source  of  finance  

•  Not  par=cularly  useful  web  or  high  growth  tech  industries  •  Some  (public)  facilita=on  for  startups  in  some  Countries  à  

i.e.  in  Italy  Fondo  di  Garanzia  will  provide  (innova=ve)  startups  with  a  (public)  collateral  on  80%  of  your  debt  up  to  €2,5M  (100+  startups  already  asked  for  it)  

Debt/  bank  finance  

Page 36: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 37: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Not  all  startups  require  external  funding  •  Cash  flow  comes  ul=mately  and  most  importantly  from  

customers,  NOT  from  investors  •  Bootstrapping  in  business  means  star=ng  a  business  without  

external  help  or  capital.  Such  startups  fund  the  development  of  their  company  through  internal  cash  flow  and  are  cau=ous  with  their  expenses.  Generally  at  the  start  of  a  venture,  a  small  amount  of  money  will  be  set  aside  for  the  bootstrap  process  

 

Customers  /  bootstrapping  

Page 38: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Focus:  bootstrapping  

h_p://bit.ly/bootstrapbible    

Page 39: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 40: Nuvolab seminar for Accelmed 2014: "Approaching investors"

3F  (aka  “Love  Capital”)  

Page 41: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 42: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  An  angel  investor  or  angel  (also  known  as  a  business  angel  or  informal  investor  or  angel  funder)  is  an  affluent  individual  who  provides  capital  for  a  business  start-­‐up,  usually  in  exchange  for  equity.    

•  A  small  but  increasing  number  of  angel  investors  organize  themselves  into  angel  groups  or  angel  networks  to  share  research  and  pool  their  investment  capital,  as  well  as  to  provide  advice  to  their  portolio  companies.  

•  Unlike  the  VC  the  Angel  invests  their  own  money  •  Hands  on  approach:  geographical  or  industrial  “proximity”  •  The  Angel  approach  is  to  invest  small  amounts  at  a  very  early  stage  /  low  valua=on  

–  €50-­‐€250k  at  valua=ons  of  €500k-­‐€4m  •  Two  “exits”  for  angel  

–  Firm  might  be  sold  quickly  for  €5-­‐10m  or  less  where  the  Angel  can  make  2-­‐5x  money  –  Firm  raises  VC  money,  ayer  which  Angel  typically  becomes  more  passive  but  has  built  up  

exposure  very  cheaply  to  a  venture  backed  enterprise  •  The  key  thing  when  selec=ng  an  Angel  therefore  is  whether  they  can  help  you  raise  VC  

finance  –  See  which  Angel  investors  have  invested  with  which  VCs    

Business  angels  

Page 43: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Digital  BAN  

Business  Angels  

Business  angels  (categories  with  Italian  examples)  

Lone  Business  Angels  

Regional  mul6sectoral  BAN  

Na6onalwide  BAN  sectoral  focus     General  BAN  

Page 44: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Example:  BAN  in  Italy  

www.iban.it    

Business  angels  (network):  map  

www.eban.org    

Page 45: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 46: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  A  venture  capital  fund  refers  to  a  pooled  investment  vehicle  that  primarily  invests  the  financial  capital  of  third-­‐party  investors  in  startup,  that  are  too  risky  for  the  standard  capital  markets  or  bank  loans.    

•  These  funds  are  typically  managed  by  a  venture  capital  firm,  which  oyen  employs  individuals  with  technology  backgrounds  (scien=sts,  researchers),  business  training  and/or  deep  industry  experience.  

•  Receive  1000s  of  business  plans  each  year  •  Read  100s  of  plans  •  Meet  with  dozens  of  companies  •  Fund  a  handful  (1-­‐2%)  •  Portolio  expecta=ons:  

–  60%  die  or  go  nowhere  (living  dead)  –  30%  yield  2-­‐4x  in  4-­‐7  years  –  10%  (hopefully  20%)  are  tremendous  successes  (e.g.,  10x,  100x,  1000x!)  

Venture  capital  

Page 47: Nuvolab seminar for Accelmed 2014: "Approaching investors"

The  Venture  Capital  inves6ng  process  

Page 48: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Structure  of  a  (generic)  VC  fund  

Page 49: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Example:  VCs  in  Italy  (Who  is  Who  map)  

www.italiastartup.it    

Venture  capital:  map  

www.evca.eu      

Page 50: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 51: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Corporate  Venture  Capital  Defini=on:  a  Venture  Capital  firm,  independent  or  cap=ve,  which  manages  at  least  on  VC  Fund  with  the  following  characteris=cs:  •  A  Corporate  is  a  cornerstone  investor  in  the  

VC  Fund  •  The  firm  is  following  the  PE  model  (exit  

strategy  and  mid  to  long  term  investment  horizon)  

•  The  VC  Fund  invests  mainly  in  companies  opera=ng  in  the  core  business  area  of  the  Corporate  

•  The  Venture  Capital  Firm  uses  extensively  the  experience,  technologies  and/or  market  contacts  of  the  Corporate  to  manage  the  portolio  of  the  VC  Fund  

 Source:  EVCA  (2013)    

Page 52: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Corporate  VC  Investment  

Source:  Boston  Consul=ng  Group  (2012)    

Page 53: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Corporate  Venture  Capital:  map  by  deals  

Page 54: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 55: Nuvolab seminar for Accelmed 2014: "Approaching investors"

REWARD-­‐BASED  

DONATION-­‐BASED  

LENDING-­‐BASED  

EQUITY-­‐BASED  

CROWDF

UNDING  M

ODE

LS  

Logic:  Proponent  à  Idea  à  Crowd  à  Reward  Target:  crea=ve  projects  (music,  cinema,  design,  hardware,  etc.).  Examples:  KickStarter  (USA/UK)  /  Eppela  (ITA)  

Logic:  Proponent  à  Cause  à  Crowd  à  Altruism  Target  :  social  /  cultural  ini=a=ves  (not  for  profit)  Examples:  Causes  (USA)  /  Rete  del  Dono  (ITA)  

Logic:  Proponent  à  Financial  need  à  Crowd  à  Interests  Target:  consumer  finance  needs  Examples:  Zopa  (UK)  /  Pres=amoci  (ITA)  

Logic:  Proponent  à  Financial  need  à  Crowd  à  Equity  Target:  startups    Examples:  AngeList  (USA)  /  GrowVC  (UK)  /  SiamoSoci  (ITA)  

Crowdfunding  Crowdfunding   is   the   prac=ce   of   funding   a   project   or   venture   by   raising  monetary   contribu6ons   from   a   large   number   of   people,   typically   via   the  Internet.    

Page 56: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  453  ac=ve  platorms  (2012)  

•  1  Million  project  funded  

•  $  0,89  Billion  raised  in  2010  

•  $1,47  Billion  raised  in  2011  

•  $2,66  Billion  raised  in  2012  

•  $5,1  Billion  raised  in  2013  (es=mate)  

Source:  Google  Trends  -­‐  Search  Volume  Index:  “crowdfunding”  

Crowdfunding  numbers  

h_p://bit.ly/thecrowdfundingbible    

Page 57: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 58: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Seed  accelerators  are  fixed-­‐term,  cohort-­‐based  programs  aimed  at  developing  new  startups.  

•  The  accelerator  programmes  key  elements  are:  - Funding,  typically  to  the  seed  level  (<€40k)  vs  equity  (5-­‐10%)  - Company  founders  are  small  teams  (2-­‐3  people)  with  technical  backgrounds  

- Each  cohort  is  supported  for  a  defined  period  of  6me  (3-­‐6  month)  

- Educa6on  programme  focusing  on  business  advice  and  product  advice  

- Networking  programme  to  meet  and/or  contact  other  investors  and  advisors  

•  Programmes  may  or  may  not  include:  –  Office  space,  whether  free  or  subsidized  –  A  Demo  Day  for  funded  companies  

Seed  accelerator  programmes  

Source:  Chris=ansen,  Jed  D.  Copying  Y  Combinator:  a  framework  for  developing  seed  accelerator  programmes.      

Prendiamo esempio da casi di successo esteri

Settembre 2011 (C) 2011 - TTAdvisor S.r.l. 8

network settoriale

network investitori

visione manageriale

completamento team

sviluppo business model

Impresa «non accelerata»

impresa «accelerata»

tempo →

dim

ensi

one →

Apparently sprinters reach their higher speed right out of the blocks, and spend the rest of the race slowing down. The winners slow down the least.

Jessica Livingston - Founders at Work

L’accelerazione agisce quando l’impresa è solo un’ idea, apportando in un periodo di tempo molto breve una spinta forte alla crescita

aumenta la crescita iniziale

la crescita rimane elevata più a lungo

L’esperienza  estera  di  accelerazione  di  impresa  ci  dice  che  questo  è  uno  strumento  efficace  per  aumentare la crescita e le probabilità di successo delle startup

Page 59: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Seed  accelerator  programmes  maps  

www.startupfactories.eu     h_p://www.seed-­‐db.com/accelerators    

Page 60: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 61: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Business  Incubators  •  Business   incubators   are  private  or   public  

organiza6on   specialized   in   crea6ng   and  suppor6ng  other  companies.  

•  According  to  NBIA  (USA  Na=onal  Business  Incuba=on  Associa=on)  there  are  10.000+  incubators  worldwide.  

•  Incubators   nurture   young   (startup)   firms  during   their   early   months   or   years,   by  usually  providing  them  with:  -  affordable/shared   offices   and   G&A  

services    -  mentoring/hands-­‐on   management  

training  /  networking  -  Oyen  marke=ng  support,  access   to  some  

form  of  financing  

Page 62: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 63: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Public  Grants  •  Grants   are   non-­‐repayable   funds   disbursed   by   one   party  

(grant   makers),   oyen   a   government   department,  corpora6on,   founda6on   or   trust,   to   a   recipient,   oyen   (but  not   always)   a   nonprofit   en=ty,   educa=onal   ins=tu=on,  business  or  an  individual.    

•  For   example,   the   European   Commission   provides   financing  through  numerous  specific  calls  for  project  proposals.  These  may   be   within   Framework   Programmes.   FP8   à   Horizon  2020:  the  programme  runs  from  2014  –2020  and  provides  an  es=mated  €80  billion  of  funding.  

•  Although   there   are   many   7   year   programmes   that   are  renewed  that  provide  money  for  various  purposes.    

•  There   are   also   occasional   one   off   grants   to   deal   with  unforeseen  aspects  or  special  projects  and  themes.  Most  of  these   are   administered   through   what   are   called   Na=onal  Agencies,  but  some  are  administered  directly  through  the  EU  Commission  in  Brussels.  

Page 64: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Founders  (and  their  bank  accounts)  Customers  Friends  &  Family  (&  Fools)  Business  angels  Venture  Capital  Corporate  Venture  Crowdfunding  Seed  accelerator  programmes  Business  incubators  Public  grants  Prizes            

Funding  sources:  short  list  

Page 65: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Prizes  •  There   are   a   lot   of   different   ini=a=ves  

worldwide   aimed   at   suppor=ng   /  celebra=ng   /   funding   brilliant   business  ideas  and  high-­‐poten=al  startups.  

•  There  are  hundreds  startup/business  plan  compe==ons   running   in   Europe,  promoted   by   public   organiza=ons,  corpora=ons,  founda=ons  and  so  on.  

•  They   can   provide   you   with   network,  coaching,   visibility,   “in   kind”   prizes   and..  some=me  money!  

Page 66: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions    

Page 67: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Network  to  gains  access  to  VCs  •  Don’t  get  hung-­‐up  on  confiden=ality  •  Be  persistent  •  Be  humble  yet  confident,  and  always  courteous  and  professional  

•  Embrace  and  learn  from  rejec=on  •  Be  greedy  in  the  long-­‐run  (any  %  of  something  >  100%  of  nothing!)  

How  to  approach  investors  

Page 68: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Large  Poten6al  Market  

Opportunity  

Unique  Product    Or  Concept  

Passionate  Founding  Team  

Pre-­‐requisites  

Intense  compe66on  

likely  

Need  to  move  rapidly  

Implica6ons…  

Hiring  

Infrastructure  

VC  funding  supports  

Rapid  Product    Development  

Interna6onalisa6on  

Partnerships  

Commercialisa6on  

Good  reasons  to  raise  equity  finance  

Page 69: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Applica6on  is  a  feature    not  a  product  

Market  size  is  too  small  

Motivation is not financial

Risk  is  not  that  you  waste  =me  unsuccessfully  trying  to  raise  finance  …  …  real  danger  is  that  you  do  succeed  in  raising  VC  funds  

–  Lose  opportunity  for  small  exit  which  could  be  personally  lucra=ve  

–  Lose  opportunity  to  run  lifestyle  business  –  Get  bound  in  to  3+  yrs  work  you  may  not  enjoy  

 

When  NOT  to  raise  VC  

Page 70: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Technology   Trac6on  

•  Can  evaluate  each  as  –  Excep=onal  –  Good  /  credible  –  Mediocre  /  incomplete  

•  Misconcep=on  that  being  good  /  credible  across  the  board  is  what  VCs  look  for  –  Can  always  add  credible  a_ributes  to  the  mix  later  

•  VCs  focus  on  finding  opportuni=es  which  rate  as  excep=onal  in  one  a_ribute  

Team  

What  does  an  investor  look  for  

Page 71: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Has  funds    to  invest  

Match  of    Size/Stage/  Geography  

Relevant  Portolio  

No  directly  compe66ve  investments  

Excellent  track  record  

Shortlist  

•  Do  create  a  shortlist  •  Rifle  is  a  be_er  weapon  

than  a  shotgun  •  Similar  process  for  

iden=fying  angels,  look  at  VC  funding  press  releases  to  iden=fy  prior  Angel  investors  

Iden6fy  relevant  VC  partners  

Page 72: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Out  of  the  blue  email  is  a  long  shot  •  Try  to  build  context  

–  Analyse  portolio  companies  –  are  there  any  links  there?  –  Analyse  contact  network  and  advisors  –  Analyse  press  coverage  –  Par=cipate  in  blog  conversa=ons  –  A_end  events  and  conferences  –  Relevant  PR  around  product  also  helps  

•  VCs  spend  their  =me  looking  for  businesses  with  momentum    

Geung  on  radar  screens  

Page 73: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Useful  sources  of  informa6on  and  inspira6on  

h_p://fundersandfounders.com     h_ps://www.techcrunch.com  h_p://startupdigest.com/  

Page 74: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions    

Page 75: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Crisis:  risk  or  opportunity?  

Page 76: Nuvolab seminar for Accelmed 2014: "Approaching investors"

…half  empty,  half  full..    It’s  just  a  maver  of  point  of  view  (and  awareness).  (At  least)  now  you  know  where  is  the  liquid(ity)!  

Conclusions  

Page 77: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Thanks  for  your  6me  &  aven6on  

@francingu @nuvolab

[email protected]

www.nuvolab.com ivysoul2000

Ref:  Francesco  Inguscio  

Page 78: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Summary  

¨ Overview    ¨ An  inconvenient  truth    ¨ Finding  funding:  different  sources    ¨ How  to  approach  investors    ¨ Conclusions  ¨  (Hidden)  bonus  track:  startup  pitch    

Page 79: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  Pitch:  What?  

•  Pitch:  Why?  

•  Pitch:  For  whom?  

•  Pitch:  How?    •  Pitch:  some  examples  à  h_p://www.pitchenvy.com  

Introduc6on  

Page 80: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Overview  

•  Problem  •  Solu=on  •  Team  •  Achievements  •  Market  •  Compe==on  •  Business  model  •  Economics  •  Investment  proposi=on  

Page 81: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Problem  

•  Analysis  of  exis6ng  and  emergent  customer  needs;      •  Analysis  of  exis6ng  solu6ons  and  their  weaknesses.  

Page 82: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Solu6on  /  Value  Proposi6on  

•  Descrip=on   of   the   offering   (product   features/   value  proposi=on)  

•  Descrip=on  of  benefits  provided  and  problems  solved    

•  Descrip=on  of  sustainable  compe==ve  advantages  (in  terms  of  technology,  product  features  and  market  needs)  

•  If  it  is  possible,  show  a  product  image  or  provide  examples  

Page 83: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Team  

•  Name,  posi=on  •  Relevant  experience  (max  2  raws)  

•  Name,  posi=on  •  Relevant  experience  (max  2  raws)  

•  Organisa=onal  chart  

•  Cap  Table  (%  equity  stake)  

Page 84: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Achievements  

•  Product  development  milestones  •  Incorpora=on  date  •  Personnel  •  Revenues  •  Metrics  (web/mobile)  •  Main  customers  •  Partnerships  •  Funding  from  founders  and  funders  •  Patents  and  trademarks  •  Compe66ve  advantages  achieved  

Page 85: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Market  

•  Iden=fica=on  of  target  market  and  of  relevant  segments  

•  Size  (in  terms  of  €/$  and  number  of  poten=al  customers)  

•  Growth  rate  (%)    

Page 86: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Compe66on  

•  Main  compe6tors;  

•  Main  market  dynamics;  

•  Main  bases  of  compe66on;  

•  Compe66ve  benchmarking.  

Page 87: Nuvolab seminar for Accelmed 2014: "Approaching investors"

•  What  is  your  business  model?  (How  do  you  make  money?)  

•  Highlights  on  sourcing,  produc=on  and  go-­‐to-­‐market  strategy  

•  Posi6oning  vis-­‐à-­‐vis  compe==on  (in  terms  of  product  features,  price,  clients,  channels)  

Business  Model  

Page 88: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Economics  €  (Euro)   2012   2013  (E)   2014  (E)   2015  (E)   2016  (E)   2017  (E)  

Revenues  

Personnel  cost  Marke=ng  Other  OPEX  

EBITDA  

EBIT  

Page 89: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Investment  proposi6on  

•  What  is  your  financial  need?  What  do  you  exactly  want  from  your  investor?  Is  there  any  chance  for  a  co-­‐investment?  With  whom?  

•  Use  of  Proceeds  (how  are  you  going  to  allocate  new  funds?)  •  Ac=vity  1  (%)  •  Ac=vity  2  (%)  •  Ac=vity  3  (%)  

•  Possible  Exit  (op+onal)  

Page 90: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Contact  name  E-­‐mail  Mobile  phone  number  Website  

Contacts  

Page 91: Nuvolab seminar for Accelmed 2014: "Approaching investors"

Pitch  Examples  (see  www.pitchenvy.com)    AirBnB  

Mint  (Intuit  $170m)    

Square